Innovative Eyewear has signed a partnership to broaden the appeal of its smart glasses, partnering with VSP-accredited Encore Optical Laboratory to handle prescription fulfilment across its online channels.
The Nasdaq-listed company, which makes smart eyewear under the Lucyd, Lucyd Armor, Reebok, Eddie Bauer and Nautica brands, said the deal brings a clutch of new lens technologies to its customers, and, with them, a broader market to sell into.
Chief among the additions is the arrival of Chemistrie lens clips, which Innovative Eyewear claims make Lucyd the first smart eyewear to offer the technology online. The system uses small magnets precision-mounted in the lenses, allowing tinted clips to attach and switch the glasses’ function, covering everything from sun protection and computer use to light sensitivity and night driving.
Alongside the clips, Lucyd frames will be offered with Zeiss PhotoFusion X lenses, a fast-reacting photochromic option aimed at customers wanting auto-tinting in a range of colours.
Harrison Gross, CEO of Innovative Eyewear, said: “From day one, we have been the smartglass company that puts correcting and protecting vision first and foremost. We have continuously pushed the envelope to offer more frame and lens options than any other smart eyewear company, because the consumer wants flexibility when it comes to their vision correction purchases.”
“We believe that for smart eyewear to achieve mass-market success, we need to offer a similar amount of variety found in traditional eyewear. “
Perhaps the most commercially significant element is Encore’s ability to cut high-index and complex prescriptions. That capability allows almost any prescription to be fitted into the Lucyd Armor smart safety range, opening the door to industrial and prescription eyeglass customers who were previously harder to serve.
The Armor range has quickly become one of Innovative Eyewear’s best-selling and accounts for a large proportion of the sales uplift in the early stage of 2026. Should Innovative Eyewear maintain its revenue growth pace through the year, it will be on course to achieve EBITDA break-even, having already invested heavily in product R&D.